未登录

L

Lisa M. Almond

certara uk ltd

H指数:19

被引数:1,572

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Physiologically Based Pharmacokinetic Modeling of Vitamin B-12 Incorporating Mechanistic Absorption: An Example Application for Intake Estimation During Pregnancy

基于生理的维生素B-12药代动力学建模：纳入机制性吸收的妊娠期摄入量估算应用实例

The Journal of Nutrition

IF3.8

2025-07-300

PRE

PBPK-Led Assessment of Antimalarial Drug Concentrations in Breastmilk: A Strategy for Optimal Use of Prediction Methods to Guide Decision Making in an Understudied Population

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2025-02-110

OAAI

Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-10-301

OAAI

A tutorial on physiologically based pharmacokinetic approaches in lactation research

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-09-163

OAAI

PBPK-led assessment of antimalarial drugs as candidates for Covid-19: Simulating concentrations at the site of action to inform repurposing strategies

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2024-07-171

OAAI

Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: Prediction of primaquine exposure as a case example

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-12-128

OA

Development and application of a PBPK modeling strategy to support antimalarial drug development

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-08-169

OAAI

Physiologically Based Pharmacokinetic Modeling To Guide Management of Drug Interactions between Elexacaftor-Tezacaftor-Ivacaftor and Antibiotics for the Treatment of Nontuberculous Mycobacteria

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2022-11-158

OA

Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2022-04-0618

OAAI

Development of physiologically-based pharmacokinetic models for standard of care and newer tuberculosis drugs

开发用于护理标准和新型结核病药物的基于生理的药代动力学模型

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2021-10-089

OAAI

Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2020-07-1631

OAAI

Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

IF4.7

2016-06-0198

OAAI

Incorporating Population Variability and Susceptible Subpopulations into Dosimetry for High-Throughput Toxicity Testing

TOXICOLOGICAL SCIENCES

IF4.1

2014-08-2179

OAAI

A Physiologically Based Pharmacokinetic Modeling Approach to Predict Disease-Drug Interactions: Suppression of CYP3A by IL-6

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2013-04-1093

PREAI

Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro-In Vivo Extrapolation Model

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2012-07-1846

OAAI

Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2005-09-01104

PREAI

Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals

奈韦拉平在人类免疫缺陷病毒感染者中的细胞内和血浆药代动力学

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2005-08-0169

PREAI

Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea

IF3.1

2002-12-0116

OAAI